News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,436 Results
Type
Article (42493)
Company Profile (295)
Press Release (675648)
Multimedia
Podcasts (79)
Webinars (12)
Section
Business (210455)
Career Advice (2091)
Deals (36631)
Drug Delivery (107)
Drug Development (83060)
Employer Resources (175)
FDA (16577)
Job Trends (15410)
News (356071)
Policy (33922)
Tag
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (90)
Alliances (51439)
ALS (92)
Alzheimer's disease (1397)
Antibody-drug conjugate (ADC) (132)
Approvals (16581)
Artificial intelligence (268)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (188)
Bladder cancer (77)
Brain cancer (29)
Breast cancer (281)
Cancer (2290)
Cardiovascular disease (183)
Career advice (1752)
Career pathing (31)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67535)
Collaboration (855)
Compensation (530)
Complete response letters (25)
COVID-19 (2661)
CRISPR (46)
C-suite (248)
Cystic fibrosis (103)
Data (2211)
Decentralized trials (2)
Denatured (28)
Depression (45)
Diabetes (274)
Diagnostics (6452)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88294)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115253)
Executive appointments (738)
FDA (17845)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (111)
Generative AI (21)
Gene therapy (318)
GLP-1 (748)
Government (4538)
Grass and pollen (5)
Guidances (59)
Healthcare (18998)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (30)
Infectious disease (2804)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16785)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (490)
Leadership (18)
Legal (8379)
Liver cancer (76)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (318)
MASH (68)
Medical device (13461)
Medtech (13466)
Mergers & acquisitions (20385)
Metabolic disorders (706)
Multiple sclerosis (80)
NASH (17)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (1951)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (39)
Obesity (377)
Opinion (229)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (239)
Patient recruitment (111)
Peanut (49)
People (59275)
Pharmaceutical (92)
Pharmacy benefit managers (19)
Phase I (20946)
Phase II (29711)
Phase III (22271)
Pipeline (1197)
Policy (151)
Postmarket research (2654)
Preclinical (8924)
Press Release (68)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (396)
Real estate (6258)
Recruiting (67)
Regulatory (23135)
Reports (46)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3726)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (43)
The Weekly (49)
Vaccines (706)
Venture capitalists (41)
Weight loss (253)
Women's health (35)
Worklife (16)
Date
Today (163)
Last 7 days (860)
Last 30 days (2664)
Last 365 days (33359)
2025 (10763)
2024 (35773)
2023 (40633)
2022 (51798)
2021 (56329)
2020 (54792)
2019 (47397)
2018 (35770)
2017 (33138)
2016 (32662)
2015 (38615)
2014 (32517)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40723)
Australia (6521)
California (6137)
Canada (2020)
China (536)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (86945)
Florida (910)
Georgia (205)
Idaho (57)
Illinois (546)
India (26)
Indiana (315)
Iowa (11)
Japan (165)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (895)
Massachusetts (4616)
Michigan (221)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1737)
New Mexico (29)
New York (1746)
North Carolina (985)
North Dakota (8)
Northern California (2677)
Ohio (203)
Oklahoma (14)
Oregon (39)
Pennsylvania (1382)
Puerto Rico (12)
Rhode Island (33)
South America (1162)
South Carolina (22)
South Dakota (1)
Southern California (2300)
Tennessee (101)
Texas (913)
United States (23255)
Utah (182)
Virginia (153)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,436 Results for "chiesi pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024.
May 16, 2024
·
6 min read
Press Releases
Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting
February 3, 2025
·
11 min read
Business
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
April 15, 2024
·
4 min read
Business
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
May 6, 2024
·
9 min read
Genetown
Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts.
June 14, 2024
·
9 min read
Genetown
Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
May 22, 2024
·
5 min read
Genetown
Chiesi Global Rare Diseases Announces Publication of Results from Fabry Disease Patient Survey
Chiesi Global Rare Diseases today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.
April 24, 2024
·
4 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
December 10, 2024
·
10 min read
Bio NC
Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Chiesi Group is continuing to experience major growth this year.
August 8, 2023
·
4 min read
Press Releases
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma, Italy
October 15, 2024
·
4 min read
1 of 71,844
Next
